ISTH 2017 Berlin revisited
ISTH Academy, Correspondence |Wolfram Ruf, 205271
What you don't know can kill you
ISTH Academy, Geoffrey Barnes, 205272
Correlates of plasma and platelet tissue factor pathway inhibitor, factor V, and Protein S
ISTH Academy, Alan Mast, 205273
Clinical outcome of patients with a vitamin K antagonist‐associated bleeding treated with prothrombin complex concentrate
ISTH Academy, Correspondence |Michiel Coppens, 205274
The role of scientific publishing in the development of early career investigators
ISTH Academy, Adam Cuker, 205275
Combined effects of two mutations in von Willebrand disease 2M phenotype
ISTH Academy, Adriana Woods, 205276
Early career professionals: A challenging road
ISTH Academy, Mandy Lauw, 205277
ISTH Academy, Session Speakers, 205278
Harold Ross Roberts, MD: inspirational mentor, consummate physician, superb scientist (1930‐2017)
ISTH Academy, Gilbert White II, 205279
A review of commercially available thrombin generation assays
ISTH Academy, Vera Ignjatovic, 205280
Lupus anticoagulant mixing tests for multiple reagents are more sensitive if interpreted with a mixing test‐specific cut‐off than index of circulating anticoagulant
ISTH Academy, Osamu Kumano, 205281
Balance, falls, and exercise: Beliefs and experiences in people with hemophilia: A qualitative study
ISTH Academy, Correspondence |Lorraine M. Flaherty, 205282
Novel therapies in thrombotic thrombocytopenic purpura
ISTH Academy, Spero Cataland, 205283
Global public awareness about atrial fibrillation
ISTH Academy, Aaron Mark Wendelboe, 205284
Current issues in diagnosis and treatment of von Willebrand disease
ISTH Academy, Veronica Flood, 205285
N‐methyl‐d‐aspartate receptor mediated calcium influx supports in vitro differentiation of normal mouse megakaryocytes but proliferation of leukemic cell lines
ISTH Academy, Maggie Kalev-Zylinska, 205286
Von Willebrand factor multimer quantitation for assessment of cardiac lesion severity and bleeding risk
ISTH Academy, Christopher Austin, 205287
Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism
ISTH Academy, Manuela Albisetti Pedroni, 205288
Platelets at the vascular interface
ISTH Academy, Wolfgang Bergmeier, 205289
Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
ISTH Academy, Correspondence |Dominique Lejeune, 205290
Acute infection as a trigger for incident venous thromboembolism: Results from a population‐based case‐crossover study
ISTH Academy, Gro Grimnes, 205291
Factor V‐short and protein S as synergistic tissue factor pathway inhibitor (TFPIα) cofactors
ISTH Academy, Björn Dahlbäck, 205292
Activity of factor XII‐Locarno
ISTH Academy, David Gailani, 205293
Randomized, double‐blind, placebo‐controlled, interventional phase IV investigation to assess the efficacy and safety of r‐hirudin gel (1120I.U) in patients with hematomas
ISTH Academy, Correspondence |Hani El‐Mowafi, 205294
Stay Coagulated and Join the ISTH Today
ISTH Academy, Session Speakers, 204867
Issue Information
ISTH Academy, Session Speakers, 204868
External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment
ISTH Academy, Ang Li, 204869
The ISTH Bleeding Assessment Tool and the risk of future bleeding
ISTH Academy, Maria Rosaria Fasulo, 204870
Joint effects of prothrombotic genotypes and body height on the risk of venous thromboembolism: the Tromsø study
ISTH Academy, Sigrid Braekkan, 204871
Evaluation of a microfluidic flow assay to screen for von Willebrand disease and low von Willebrand factor levels
ISTH Academy, Christopher Ng, 204872
The identification of at‐risk patients and prevention of venous thromboembolism in pediatric cancer: guidance from the SSC of the ISTH
ISTH Academy, Jay Michael S. Balagtas, 204873
Fibrin fuels fatty liver disease
ISTH Academy, Ton Lisman, 204874
Effects of low‐dose epinephrine on perioperative hemostasis and inflammatory reaction in major surgical operations: a randomized clinical trial
ISTH Academy, Liu Yang, 204875
Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers
ISTH Academy, Jerrold H. Levy, 204876
Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study
ISTH Academy, Maarten B. Rookmaker, 204877
ADAMTS‐13 and von Willebrand factor: a dynamic duo
ISTH Academy, David Lane, 204878
Use of factor concentrates for the management of perioperative bleeding: guidance from the SSC of the ISTH
ISTH Academy, Anne Godier, 204879
What the neighbors say
ISTH Academy, Session Speakers, 204880
Natural antibodies to oxidation‐specific epitopes: innate immune response and venous thromboembolic disease
ISTH Academy, Sabine Eichinger, 204881
Targeting of C‐type lectin‐like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides: comment
ISTH Academy, Ulrike Flierl, 204882
Associations of activated coagulation factor VII and factor VIIa‐antithrombin levels with genome‐wide polymorphisms and cardiovascular disease risk
ISTH Academy, Russell Tracy, 204883
Receptor homodimerization plays a critical role in a novel dominant negative P2RY12 variant identified in a family with severe bleeding
ISTH Academy, Marie-Christine Morel-Kopp, 204884
Platelet rescue by macrophage depletion in obese ADAMTS‐13‐deficient mice at risk of thrombotic thrombocytopenic purpura
ISTH Academy, H Lijnen, 204885
Timing and severity of inhibitor development in recombinant versus plasma‐derived factor VIII concentrates: a SIPPET analysis
ISTH Academy, Flora Peyvandi, 204886
Aging of the venous valves as a new risk factor for venous thrombosis in the elderly: the BATAVIA study
ISTH Academy, Astrid Van Hylckama Vlieg, 204887
Characteristics and quality of oral anticoagulation treatment in pediatric patients in the Netherlands based on the CAPS cohort
ISTH Academy, Anthonius de Boer, 204888
SIPPET: insights into factor VIII immunogenicity
ISTH Academy, James O'Donnell, 204889
Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α‐chain crosslinking
ISTH Academy, Alisa Wolberg, 204890
Neighborhood watch
ISTH Academy, Session Speakers, 204891
Cancer and risk of cerebral venous thrombosis: a case–control study
ISTH Academy, Jonathan Coutinho, 204892
International collaborative study for the calibration of proposed International Standards for thromboplastin, rabbit, plain, and for thromboplastin, recombinant, human, plain
ISTH Academy, Ton van den Besselaar, 204893
Targeting of C‐type lectin‐like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides: reply
ISTH Academy, Cecile Oury, 204894
Elevated preoperative von Willebrand factor is associated with perioperative thrombosis in infants and neonates with congenital heart disease
ISTH Academy, Juan C. Ibla, 203869
Plasminogen activator inhibitor‐1 regulates the vascular expression of vitronectin
ISTH Academy, Jianbo Wu, 203870
Evaluation of the age‐dependent dosing recommendations for the administration of daily tinzaparin in children with thrombosis
ISTH Academy, Kathryn M. Musgrave, 203871
Retinoic acid receptor‐α regulates synthetic events in human platelets
ISTH Academy, Hansjorg Schwertz, 203872
The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran: comment
ISTH Academy, Luke Yip, 203873
Relationship between neighborhood socioeconomic status and venous thromboembolism: results from a population‐based study
ISTH Academy, Willem Lijfering, 203874
Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations
ISTH Academy, Jeffrey I. Weitz, 203875
Harold Ross Roberts, M.D: inspirational mentor, consummate physician, superb scientist (1930–2017)
ISTH Academy, Session Speakers, 203876
Antiphospholipid antibody‐induced cellular responses depend on epitope specificity : implications for treatment of antiphospholipid syndrome
ISTH Academy, Karl Lackner, 203877
Inherited thrombocytopenia caused by ANKRD26 mutations misdiagnosed and treated as myelodysplastic syndrome: report on two cases
ISTH Academy, Alessandro Pecci, 203878
Venous thromboembolism and risk of cancer in patients with rheumatoid arthritis
ISTH Academy, Alma B. Pedersen, 203879
ISTH Academy, Session Speakers, 203880
Soluble fibrin causes an acquired platelet glycoprotein VI signaling defect: implications for coagulopathy
ISTH Academy, Scott Diamond, 203881
Long‐term mental wellbeing of adolescents and young adults diagnosed with venous thromboembolism: results from a multistage mixed methods study
ISTH Academy, Anette Hojen, 203882
What the neighbors say
ISTH Academy, Session Speakers, 203883
Soluble fibrin going for six
ISTH Academy, Samantha J. Montague, 203884
Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH
ISTH Academy, Dr. Alfonso Iorio, 203885
Is there also room for rational thought?
ISTH Academy, Session Speakers, 203886
Stay Coagulated and Join the ISTH Today
ISTH Academy, Session Speakers, 203887
Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice
ISTH Academy, Karen Vanhoorelbeke, 203888
Repeated measurements of carotid atherosclerosis and future risk of venous thromboembolism: the Tromsø Study
ISTH Academy, Birgit Sm�brekke, 203889
Tissue factor‐bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer
ISTH Academy, Kathryn Date, 203890
Aerobic exercise training lowers platelet reactivity and improves platelet sensitivity to prostacyclin in pre‐ and postmenopausal women
ISTH Academy, Martina Helena Lundberg Slingsby, 203891
Issue Information
ISTH Academy, Session Speakers, 203892
Implementation of buffy‐coat‐derived pooled platelet concentrates for internal quality control of light transmission aggregometry: a proof of concept study
ISTH Academy, Harald Mangge, 203893
A large case series on surgical outcomes in congenital factor XIII deficiency patients in Iran
ISTH Academy, Mehran Karimi, 203894
No added value of the age‐adjusted D‐dimer cut‐off to the YEARS algorithm in patients with suspected pulmonary embolism
ISTH Academy, Frederikus Klok, 203895
Management of patients with bleeding disorders
ISTH Academy, Robert L. Reid & Nigel S. Key, 203690
Issue Information
ISTH Academy, Session Speakers, 203257
Minimal factor XIII activity level to prevent major spontaneous bleeds: comment
ISTH Academy, Majid Naderi, 203258
Human pancreatic tumors grown in mice release tissue factor‐positive microvesicles that increase venous clot size
ISTH Academy, Nigel mackman, 203259
Extended pharmacologic thromboprophylaxis in oncologic liver surgery is safe and effective
ISTH Academy, Thomas A. Aloia, 203260
Emil Alfred Loeliger (Zürich 28 June 1924–Leiden 29 May 2017)
ISTH Academy, Session Speakers, 203261
An αβ antagonist prevents thrombosis without causing Fc receptor γ‐chain IIa‐mediated thrombocytopenia
ISTH Academy, Tur-Fu Huang, 203262
Extramedullary hematopoiesis: a new feature of inherited thrombocytopenias?
ISTH Academy, Carlo Zaninetti, 203263
Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability
ISTH Academy, Jacqueline Halton, 203264
Reversal of apixaban anticoagulation by four‐factor prothrombin complex concentrates in healthy subjects: a randomized three‐period crossover study
ISTH Academy, Charles Frost, 203265
A novel protein C–factor VII chimera provides new insights into the structural requirements for cytoprotective protease‐activated receptor 1 signaling
ISTH Academy, Roger Preston, 203266
What the neighbors say
ISTH Academy, Session Speakers, 203273
Disease prevalence dependent failure rate in diagnostic management studies on suspected deep vein thrombosis: communication from the SSC of the ISTH
ISTH Academy, Frederikus Klok, 203274
Minimal factor XIII activity level to prevent major spontaneous bleeds: reply
ISTH Academy, Marzia Menegatti, 203275
Advanced cell‐based modeling of the royal disease: characterization of the mutated F9 mRNA
ISTH Academy, Jordi Barquinero, 203276
Predicting the risk of cancer after unprovoked venous thromboembolism: external validation of the RIETE score
ISTH Academy, Laurent Bertoletti, 203277
Thrombin‐activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease
ISTH Academy, Robert Ariens, 203278
Clinical course of patients with symptomatic isolated superficial vein thrombosis: the ICARO follow‐up study
ISTH Academy, Francesco Dentali, 203279
ISTH Academy, Session Speakers, 203280
Stay Coagulated and Join the ISTH Today
ISTH Academy, Session Speakers, 203281
A gain‐of‐function mutation in TNFRSF13B is a candidate for predisposition to familial or sporadic immune thrombocytopenia
ISTH Academy, GuangSen Zhang, 203282

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings